News
NEO
14.24
+2.52%
0.35
Weekly Report: what happened at NEO last week (0513-0517)?
Weekly Report · 05/20 11:07
Weekly Report: what happened at NEO last week (0506-0510)?
Weekly Report · 05/13 11:17
NeoGenomics Earnings Analysis: Q1 Recap
NeoGenomics beat estimated earnings by 60.0% on April 30, 2024. Revenue was up $19.02 million from the same period last year. The company provided guidance for FY 2024. NeoGenomics's peers include BrightSpring Health, Guardant Health, and R1 RCM.
Benzinga · 05/10 11:21
Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
TipRanks · 05/06 12:28
Weekly Report: what happened at NEO last week (0429-0503)?
Weekly Report · 05/06 11:24
NeoGenomics Price Target Cut to $21.00/Share From $23.00 by BTIG
Dow Jones · 05/02 17:53
NeoGenomics Is Maintained at Buy by BTIG
Dow Jones · 05/02 17:53
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
Benzinga · 05/02 17:43
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
TipRanks · 05/02 10:40
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Mastercard, Metagenomi, Ziff Davis and 3M among companies. Analyst cuts target price to $510 from $520 for Mastercard. 3M raises price objective to $105 from $100.
Reuters · 05/02 07:12
Buy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth Prospects
TipRanks · 05/02 06:15
NEOGENOMICS INC <NEO.O>: BTIG CUTS TARGET PRICE TO $21 FROM $23
Reuters · 05/02 06:11
NeoGenomics Price Target Cut to $20.00/Share From $21.00 by TD Cowen
Dow Jones · 05/01 17:59
NeoGenomics Is Maintained at Buy by TD Cowen
Dow Jones · 05/01 17:59
TD Cowen Maintains Buy on NeoGenomics, Lowers Price Target to $20
Benzinga · 05/01 17:49
NeoGenomics Price Target Announced at $26.00/Share by Craig-Hallum
Dow Jones · 05/01 17:31
NeoGenomics Coverage Assumed by Craig-Hallum at Buy
Dow Jones · 05/01 17:31
Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
Benzinga · 05/01 17:21
NeoGenomics Price Target Maintained With a $18.00/Share by Benchmark
Dow Jones · 05/01 15:30
Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Benzinga · 05/01 15:19
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.